α1-Adrenoceptor subtypes and lower urinary tract symptoms

International Journal of Urology

Volumn 15, Issue 3, 2008, Pages 193-199

  Schwinn, Debra A ^a   Roehrborn, Claus G ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adrenergic; Adrenoceptor; Alpha blockers; Benign prostatic hyperplasia; BPH; Prostate

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORTALIDONE; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; MESSENGER RNA; MUSCARINIC RECEPTOR BLOCKING AGENT; NAFTOPIDIL; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SILDENAFIL; SILODOSIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TADALAFIL; TAMSULOSIN; TERAZOSIN; VARDENAFIL;

ASTHENIA; BACKACHE; BLOOD PRESSURE FLUCTUATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIZZINESS; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPNEA; EDEMA; EJACULATION; ELDERLY CARE; ERECTILE DYSFUNCTION; FATIGUE; FLU LIKE SYNDROME; FLUSHING; FOLLOW UP; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; IMPOTENCE; INFECTION; INTRAOPERATIVE FLOPPY IRIS SYNDROME; IRIS DISEASE; LOWER URINARY TRACT SYMPTOM; MEN'S HEALTH; MONOTHERAPY; NAUSEA; NONHUMAN; NOSE CONGESTION; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; RABBIT; RANDOMIZED CONTROLLED TRIAL; REVIEW; RHINITIS; RISK ASSESSMENT; SCORING SYSTEM; SIDE EFFECT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE; SOMNOLENCE; TISSUE DISTRIBUTION; TRANSRECTAL ULTRASONOGRAPHY; UNSPECIFIED SIDE EFFECT; URINARY TRACT OBSTRUCTION; URINARY TRACT SURGERY; URINE FLOW RATE; XEROSTOMIA; CLASSIFICATION; MALE; PROSTATISM;

CLINICAL TRIALS AS TOPIC; HUMANS; MALE; PROSTATISM; RECEPTORS, ADRENERGIC, ALPHA-1;

EID: 39849096422     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2007.01956.x     Document Type: Review

References (59)

1. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J. Urol. 2003 170 : 530 47.
2. Docherty JR. Subtypes of functional alpha1- and alpha2-adrenoceptors. Eur. J. Pharmacol. 1998 361 : 1 15.
3. Hieble JP, Bylund DB, Clarke DE, Eikenburg DC, Langer SZ, Lefkowitz RJ, Minneman KP, Ruffolo RR Jr. International union of pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. Pharmacol. Rev. 1995 47 : 267 70.
4. Hawrylyshyn KA, Michelotti GA, Coge F, Guenin SP, Schwinn DA. Update on human alpha1-adrenoceptor subtype signaling and genomic organization. Trends Pharmacol. Sci. 2004 25 : 449 55.
5. Richardson CD, Donatucci CF, Page SO, Wilson KH, Schwinn DA. Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes. Prostate 1997 33 : 55 9.
6. Schwinn DA, Johnston GI, Page SO et al. Cloning and pharmacological characterization of human alpha-1 adrenergic receptors: sequence corrections and direct comparison with other species homologues. J. Pharmacol. Exp. Ther. 1995 272 : 134 42.
7. Price DT, Lefkowitz RJ, Caron MG, Berkowitz D, Schwinn DA. Localization of mRNA for three distinct alpha 1-adrenergic receptor subtypes in human tissues: implications for human alpha-adrenergic physiology. Mol. Pharmacol. 1994 45 : 171 5.
8. Andersson KE, Lepor H, Wyllie MG. Prostatic alpha 1-adrenoceptors and uroselectivity. Prostate 1997 30 : 202 15.
9. Kojima Y, Sasaki S, Shinoura H et al. Change of expression levels of alpha1-adrenoceptor subtypes by administration of alpha1d-adrenoceptor-subtype- selective antagonist naftopidil in benign prostate hyperplasia patients. Prostate 2007 67 : 1285 92.
10. Smith M, Schambra U, Wilson K, Page S, Schwinn D. Alpha1-adrenergic receptors in human spinal cored: specific localized expression of mRNA encoding alpha1-adrenergic receptor subtypes at four distinct levels. Mol. Brain Res. 1999 63 : 254 61.
11. Malloy BJ, Price DT, Price RR et al. Alpha1-adrenergic receptor subtypes in human detrusor. J. Urol. 1998 160 : 937 43.
12. 1a-adrenoceptor antagonist, in men with benign prostatic hyperplasia (BPH) [abstract]. Proceedings of the Fifth International Consultation on BPH 2000 : 550.
13. Bouchelouche K, Andersen L, Alvarez S, Nordling J, Bouchelouche P. Increased contractile response to phenylephrine in detrusor of patients with bladder outlet obstruction: effect of the alpha1A and alpha1D-adrenergic receptor antagonist tamsulosin. J. Urol. 2005 173 : 657 61.
14. Nishino Y, Masue T, Miwa K, Takahashi Y, Ishihara S, Deguchi T. Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study. Br. J. Urol. 2006 97 : 747 51.
15. Takahashi S, Tajima A, Matsushima H, Kawamura T, Tominage T, Kitamura T. Clinical efficacy of an alpha1A/d-adrenoceptor blocker (naftopidil) on overactive bladder symptoms in patients with benign prostatic hyperplasia. Int. J. Urol. 2006 13 : 15 20.
16. Ishizuka O, Persson K, Mattiasson A, Naylor A, Wyllie M, Andersson K. Micturition in conscious rats with and without bladder outlet obstruction: role of spinal alpha 1-adrenoceptors. Br. J. Pharmacol. 1996 117 : 962 6.
17. Ohtake A, Ukai M, Saitoh C et al. Effect of tamsulosin on spontaneous bladder contraction in conscious rats with bladder outlet obstruction: comparison with effect on intraurethral pressure. Eur. J. Pharmacol. 2006 545 : 185 91.
18. Nomiya M, Yamaguchi O. Functional and anatomical effects of hormonally induced experimental prostate growth: a urodynamic model of benign prostatic hyperplasia (BPH) in the beagle. Prostate 2003 58 : 156 63.
19. Ishihama H, Momota Y, Yanase H, Wang X, de Groat W, Kawatani M. Activation of alpha1D adrenergic receptors in the rat urothelium facilitates the micturition reflex. J. Urol. 2006 175 : 358 64.
20. Yokoyama O, Yusup A, Oyama N, Aoki Y, Miwa Y, Akino H. Improvement in bladder storage function by tamsulosin depends on suppression of C-fiber urethral afferent activity in rats. J. Urol. 2007 177 : 771 5.
21. Rudner X, Berkowitz D, Booth J et al. Subtype specific regulation of human vascular alpha(1)-adrenergic receptors by vessel bed and age. Circulation 1999 100 : 2336 43.
22. de Mey C, Michel MC, McEwen J, Moreland T. A double-blind comparison of terazosin and tamsulosin on their differential effects on ambulatory blood pressure and nocturnal orthostatic stress testing. Eur. Urol. 1998 33 : 481 8.
23. Souverein PC, Van Staa TP, Egberts AC, De la Rosette JJ, Cooper C, Leufkens HG. Use of alpha-blockers and the risk of hip/femur fractures. J. Intern. Med. 2003 254 : 548 54.
24. Gotoh M, Kamihira O, Kinukawa T, Ono Y, Ohshima S, Origasa H, Group TUCT. Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial. Br. J. Urol. 2005 96 : 581 6.
25. de Mey C. Cardiovascular effects of alpha-blockers for the treatment of symptomatic BPH. Eur. Urol. 1998 34 Suppl. 2 : 18 28 discussion 47.
26. Nickel JC. The use of alpha1-adrenoceptor antagonists in lower urinary tract symptoms: beyond benign prostatic hyperplasia. Urology 2003 62 : 34 41.
27. Harada K, Ohmori M, Kitoh Y, Sugimoto K, Fujimura A. A comparison of the antagonistic activities of tamsulosin and terazosin against human vascular alpha1-adrenoceptors. Jpn. J. Pharmacol. 1999 80 : 209 15.
28. Masumori N, Hashimoto J, Itoh N, Tsukamoto T, Group TS. Short-term efficacy and long-term compliance/treatment failure of the alpha-1 blocker naftopidil for patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Scand. J. Urol. Nephrol. 2007 41 : 422 9.
29. Ikemoto K, Kiyota H, Ohishi Y et al. Usefulness of tamsulosin hydrochloride and naftopidil in patients with urinary disturbances caused by benign prostatic hyperplasia: a comparative, randomized, two-drug crossover study. Int. J. Urol. 2003 10 : 587 94.
30. Wilde MI, Fitton A, Sorkin EM. Terazosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs Aging 1993 3 : 258 77.
31. Fulton B, Wagstaff AJ, Sorkin EM. Doxazosin. An update of its clinical pharmacology and therapeutic applications in hypertension and benign prostatic hyperplasia. Drugs 1995 49 : 295 320.
32. Wilde MI, Fitton A, McTavish D. Alfuzosin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in benign prostatic hyperplasia. Drugs 1993 45 : 410 29.
33. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998 51 : 892 900.
34. Hisasue S, Furuya R, Itoh N, Kobayashi K, Furuya S, Tsukamoto T. Ejaculatory disorder caused by alpha-1 adrenoceptor antagonists is not retrograde ejaculation but a loss of seminal emission. Int. J. Urol. 2006 13 : 1311 16.
35. Hellstrom WJ Sikka SC. Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. J Urol 2006 176 : 1529 1533.
36. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003 42 : 1206 52.
37. Albertsen PC, Pellissier JM, Lowe FC, Girman CJ, Roehrborn CG. Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study. Clin. Ther. 1999 21 : 1006 24.
38. McConnell JD, Bruskewitz R, Walsh P et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N. Engl. J. Med. 1998 338 : 557 63.
39. McConnell JD, Roehrborn CG, Bautista OM et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N. Engl. J. Med. 2003 349 : 2387 98.
40. Roehrborn CG, Boyle P, Nickel JC, Hoefner K, Andriole G. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology 2002 60 : 434 41.
41. Wilt TJ, Ishani A, Stark G, MacDonald R, Lau J, Mulrow C. Saw palmetto extracts for treatment of benign prostatic hyperplasia: a systematic review. JAMA 1998 280 : 1604 9.
42. Wilt T, Ishani A, MacDonald R, Rutks I, Stark G. Pygeum africanum for benign prostatic hyperplasia. Cochrane Database Syst. Rev. 2002 : CD001044.
43. Yamanishi T, Yasuda K, Kamai T et al. Single-blind, randomized controlled study of the clinical and urodynamic effects of an alpha-blocker (naftopidil) and phytotherapy (eviprostat) in the treatment of benign prostatic hyperplasia. Int. J. Urol. 2004 11 : 501 9.
44. Roehrborn CG, Abrams P, Rovner ES, Kaplan SA, Herschorn S, Guan Z. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. BJU Int. 2006 97 : 1003 6.
45. Brawer MK, Lin DW, Williford WO, Jones K, Lepor H. Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359. Prostate 1999 39 : 234 9.
46. McConnell JD. MSC: the long term effects of medical therapy on the progression of BPH: results from the MTOPS trial. J. Urol. 2002 167 : 1042.
47. Kirby RS, Roehrborn C, Boyle P et al. Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial. Urology 2003 61 : 119 26.
48. McAuley IW, Kim NN, Min K, Goldstein I, Traish AM. Intracavernosal sildenafil facilitates penile erection independent of the nitric oxide pathway. J. Androl. 2001 22 : 623 8.
49. O'Leary MP. Lower urinary tract symptoms/benign prostatic hyperplasia: maintaining symptom control and reducing complications. Urology 2003 62 : 15 23.
50. Rosen R, Altwein J, Boyle P et al. Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur. Urol. 2003 44 : 637 49.
51. Palea S, Barras M. Comparison of the relaxant effects of alfuzosin, phentolamine and sildenafil on rabbit isolated corpus cavernosum. BJU Int. 2003 91 : 873 7.
52. Mizusawa H, Hedlund P, Sjunnesson J, Brioni JD, Sullivan JP, Andersson KE. Enhancement of apomorphine-induced penile erection in the rat by a selective alpha(1D)-adrenoceptor antagonist. Br. J. Pharmacol. 2002 136 : 701 8.
53. Kloner RA. Sex and the patient with cardiovascular risk factors: focus on sildenafil. Am. J. Med. 2000 109 (Suppl. 9A 13S 21S discussion 29S 30S.
54. Webb DJ, Muirhead GJ, Wulff M, Sutton JA, Levi R, Dinsmore WW. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J. Am. Coll. Cardiol. 2000 36 : 25 31.
55. Sairam K, Kulinskaya E, McNicholas TA, Boustead GB, Hanbury DC. Sildenafil influences lower urinary tract symptoms. BJU Int. 2002 90 : 836 9.
56. McVary KT, Monnig W, Camps JL Jr, Young JM, Tseng LJ, van den Ende G. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J. Urol. 2007 177 : 1071 7.
57. McVary KT, Roehrborn CG, Kaminetsky JC et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J. Urol. 2007 177 : 1401 7.
58. Schwinn D. Alpha(1)-adrenergic receptor antagonists and the iris: new mechanistic insights into floppy iris syndrome. Surv Ophthalmol. 2006 51 : 501 12.
59. Michel M, Okutsu H, Noguchi Y et al. In vivo studies on the effects of alpha1-adrenoceptor antagonists on pupil diameter and urethral tone in rabbits. Naunyn Schmiedebergs Arch. Pharmacol. 2006 372 : 346 53.